Scientists reverse Alzheimer's memory loss in mice by using NAD+ to restore brain energy, defying decades of research.

The NHS will reconsider approving two Alzheimer’s “wonder drugs” after a successful appeal. The National Institute of Health and Care Excellence , which assesses the cost-ef ...

Oral semaglutide (a GLP-1 pill) is not effective at slowing progression in patients with mild Alzheimer's disease, finds the ...

Lecanemab, which will be available under the name Leqembi, can slow the cognitive decline associated with Alzheimer’s disease by 27%, according to data submitted to the FDA by the drug’s developers, ...

Following successful appeals from drugmakers, the U.K. is taking another look at whether two new Alzheimer's drugs can be considered cost-effective.

The NHS spending watchdog must look again at its decision after drug manufacturers successfully appealed against Nice's ruling that the treatments were not cost-effective ...

Evoke and Evoke+ -- the randomized, double-blind, placebo-controlled phase 3 trials conducted across 566 sites in 40 ...

A recent study published in the journal Molecular Psychiatry provides evidence that a combination of non-invasive brain scanning and computer modeling can successfully measure how a dementia drug ...

A key Alzheimer’s drug has finally revealed its secret. Researchers discovered that lecanemab works by activating the brain’s immune cells—but only through a specific part of the antibody called the ...

After a successful appeal, reimbursement authority NICE has said the companies' files will now be sent back to the appraisal ...

NHS watchdogs will re-evaluate their decision not to fund two new Alzheimer’s treatments on the health service after appeals from the drugs’ manufacturers. The National Institute for Health and Care ...

In the brain, Alzheimer’s is characterized by two proteins, amyloid beta and tau, that become dysfunctional, forming plaques ...